Stockscreener 앱 받기
4.675
3.61%
-0.175
전일 마감가:
$4.85
열려 있는:
$5.2889
하루 거래량:
8,308
Relative Volume:
0.40
시가총액:
$36.85M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-12.62%
1개월 성능:
+15.43%
6개월 성능:
-4.59%
1년 성능:
+0.00%
1일 변동 폭
$4.63
$5.2889
1주일 범위
$4.59
$5.75
52주 변동 폭
$3.4962
$50.82
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
RADX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
4.675 | 39.28M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-12 | 개시 | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr 주식(RADX)의 최신 뉴스
Radiopharm Theranostics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Radiopharm Theranostics Limited: Promising Clinical Developments and Strategic Growth Potential Drive Buy Rating - TipRanks
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody By Investing.com - Investing.com India
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody - Investing.com
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) By Investing.com - Investing.com India
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) - Investing.com
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board - GlobeNewswire Inc.
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board By Investing.com - Investing.com India
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board - Investing.com
Radiopharm Theranostics (NASDAQ:RADX) Now Covered by Brookline Capital Management - Defense World
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital - Investing.com
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital By Investing.com - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive By Investing.com - Investing.com South Africa
OKYO Pharma (NASDAQ:OKYO) Trading Up 1% – Here’s Why - Defense World
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and COMPASS Pathways (CMPS) - The Globe and Mail
Radiopharm signs supply agreement with Cyclotek for prostate cancer drug - Investing.com
Radiopharm wins FDA fast track for cancer imaging agent By Investing.com - Investing.com South Africa
Radiopharm wins FDA fast track for cancer imaging agent - Investing.com
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
radiopharm theranostics begins patient dosing in new trial - Investing.com
radiopharm theranostics begins patient dosing in new trial By Investing.com - Investing.com India
radiopharm theranostics shares preclinical data on new cancer therapy By Investing.com - Investing.com South Africa
radiopharm theranostics shares preclinical data on new cancer therapy - Investing.com
Radiopharm secures lutetium-177 supply agreement By Investing.com - Investing.com South Africa
Radiopharm Theranostics Secures Lutetium-177 Supply Agreement with ITM - TipRanks
Radiopharm secures lutetium-177 supply agreement - Investing.com
Radiopharm advances RAD204 trial with expedited phase By Investing.com - Investing.com India
Radiopharm advances RAD204 trial with expedited phase - Investing.com
RADX: Initiating Coverage – Adding a Radioisotope to Precision Oncology - Zacks Small Cap Research
ThinkEquity initiates Radiopharm stock with Buy, $15 target By Investing.com - Investing.com India
ThinkEquity initiates Radiopharm stock with Buy, $15 target - Investing.com
Radiopharm advances brain cancer diagnosis with new trial By Investing.com - Investing.com South Africa
Radiopharm advances brain cancer diagnosis with new trial - Investing.com
Radiopharm Theranostics says new data confirms positive tumour uptake - Biotech Dispatch
Radiopharm Theranostics Engages in Key Healthcare Conferences - TipRanks
B.Riley sets $15 target on Radiopharm Theranostics stock - Investing.com India
Radiopharm Theranostics Announces Director’s Interest Change and Securities Cessation - TipRanks
Radiopharm joins B Riley Radiopharma Conference - Investing.com
Radiopharm reveals positive brain metastases trial data - Investing.com India
Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
Radiopharm Theranostics Ltd Adr (RADX) 재무 분석
Radiopharm Theranostics Ltd Adr (RADX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):